LoginSign Up
SyntheX

SyntheX

SyntheX is a biotechnology and pharmaceutical company headquartered in San Francisco, California that was founded in 2016 by Charly Chahwan and Maria Soloveychik developing treatments for cancer and other diseases.

SyntheX is a biotechnology and pharmaceutical company that was founded by Charly Chahwan and Maria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.

Funding

Convertible note

On March 10, 2016 SyntheX received a convertible note worth $250 thousand from SOSV and IndieBio.

Seed round

On April 20, 2017 SyntheX closed their seed funding round with $6.2 million in seed round funding from Morgan Noble, SOSV, Oriza Ventures, and 8VC.

Timeline

People

Name
Role
Related Golden topics

Charly Chahwan

Founder

Maria Soloveychik

Founder

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References